InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPRGet Rating) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the stock.

InspireMD Price Performance

NYSE:NSPR opened at $1.11 on Monday. The stock’s 50 day moving average price is $1.25 and its 200 day moving average price is $1.71. InspireMD has a 52-week low of $0.81 and a 52-week high of $3.75. The company has a market capitalization of $9.26 million, a PE ratio of -0.49 and a beta of 1.06.

InspireMD Company Profile

(Get Rating)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

See Also

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.